source
- Lilly sues over black-market retatrutide; Neurocrine's new obesity drug linked to patient deathsEli Lilly has filed six lawsuits against U.S. companies it says are illegally selling black-market versions of its experimental obesity drug retatrutide. The company alleges the defendants are dist…
- Silence Therapeutics' Phase 2 trial shows strong results for divesiran in polycythemia vera, shares jump 30%Silence Therapeutics reported that its nucleic‑acid drug divesiran achieved a 69% placebo‑adjusted response rate in a Phase 2 study of polycythemia vera patients. Safety was reported as clean, with…